[在非小细胞肺癌中BRAF基因改变的进展]
Libian Deng1, Yaxian Yang2, Jian Huang3
1Department of Pathology, The Second Affiliated Hospital of Guangdong Medical University, Zhanjiang 524002, China.
Zhongguo fei ai za zhi = Chinese journal of lung cancer
|January 31, 2024
概括
BRAF的改变驱动非小细胞肺癌 (NSCLC). 针对BRAF和MEK的组合疗法提供个性化治疗,但需要克服耐药性并改善非V600突变的结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 病毒性瘤基因同源B (BRAF) 突变是非小细胞肺癌 (NSCLC) 的关键驱动因素.
- BRAF突变激活了线粒激活蛋白激酶激酶 (MEK) 信号通路,促进了癌细胞的生长.
- 针对BRAF和MEK为具有特定突变的NSCLC患者提供了个性化的治疗机会.
研究的目的:
- 审查NSCLC中BRAF基因的结构特征,信号通路和突变类型.
- 探索BRAF突变和NSCLC之间的临床和病理关系.
- 总结BRAF驱动的NSCLC当前和新兴的治疗策略.
主要方法:
- 关于NSCLC中BRAF基因结构,功能和突变的文献综述.
- 分析涉及BRAF和MEK的信号通路.
- 对BRAF突变NSCLC的临床数据和治疗结果的审查.
主要成果:
- BRAF突变,特别是非V600类型,在治疗疗效和持续时间方面存在挑战.
- 耐药性和有限的治疗效果是BRAF驱动的NSCLC的重大障碍.
- 组合疗法对于克服治疗耐药性和改善治疗结果至关重要.
结论:
- 了解BRAF的结构和信号作用对于NSCLC治疗至关重要.
- 需要对BRAF突变亚型和耐药性的进一步研究.
- 对BRAF驱动的NSCLC的基于证据的治疗决策可以通过对治疗选择的全面审查来改进.
更多相关视频
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
24.4K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
相关概念视频
01:20The Retinoblastoma Gene
4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
02:38The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K